216 related articles for article (PubMed ID: 24286114)
1. Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia.
Spaeth M; Alegre C; Perrot S; Wang Y; Guinta DR; Alvarez-Horine S; Russell I;
Arthritis Res Ther; 2013 Nov; 15(6):R185. PubMed ID: 24286114
[TBL] [Abstract][Full Text] [Related]
2. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study.
Russell JI; Holman AJ; Swick TJ; Alvarez-Horine S; Wang GY; Guinta D;
Pain; 2011 May; 152(5):1007-1017. PubMed ID: 21397402
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
[TBL] [Abstract][Full Text] [Related]
4. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial.
Spaeth M; Bennett RM; Benson BA; Wang YG; Lai C; Choy EH
Ann Rheum Dis; 2012 Jun; 71(6):935-42. PubMed ID: 22294641
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
[TBL] [Abstract][Full Text] [Related]
6. Sodium oxybate for the treatment of fibromyalgia.
Staud R
Expert Opin Pharmacother; 2011 Aug; 12(11):1789-98. PubMed ID: 21679091
[TBL] [Abstract][Full Text] [Related]
7. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial.
Russell IJ; Perkins AT; Michalek JE;
Arthritis Rheum; 2009 Jan; 60(1):299-309. PubMed ID: 19116896
[TBL] [Abstract][Full Text] [Related]
8. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
Arnold LM; Bateman L; Palmer RH; Lin Y
Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278
[TBL] [Abstract][Full Text] [Related]
9. Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
Husain AM; Bujanover S; Ryan R; Scheckner B; Black J; Profant J
J Clin Sleep Med; 2020 Sep; 16(9):1469-1474. PubMed ID: 32356515
[TBL] [Abstract][Full Text] [Related]
10. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
Clauw DJ; Mease P; Palmer RH; Gendreau RM; Wang Y
Clin Ther; 2008 Nov; 30(11):1988-2004. PubMed ID: 19108787
[TBL] [Abstract][Full Text] [Related]
11. A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy.
Mamelak M; Swick T; Emsellem H; Montplaisir J; Lai C; Black J
Sleep Med; 2015 Jan; 16(1):52-8. PubMed ID: 25533539
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
[TBL] [Abstract][Full Text] [Related]
13. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
[TBL] [Abstract][Full Text] [Related]
14. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia.
Arnold LM; Emir B; Murphy TK; Zeiher BG; Pauer L; Scott G; Petersel D
Clin Ther; 2012 May; 34(5):1092-102. PubMed ID: 22503162
[TBL] [Abstract][Full Text] [Related]
15. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
Dauvilliers Y; Šonka K; Bogan RK; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Chen A; Black J; Skobieranda F; Thorpy MJ
CNS Drugs; 2022 Jun; 36(6):633-647. PubMed ID: 35635687
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia.
Morse AM; Dauvilliers Y; Arnulf I; Thorpy MJ; Foldvary-Schaefer N; Chandler P; Chen A; Hickey L; Black J; Bogan RK
J Clin Sleep Med; 2023 Oct; 19(10):1811-1822. PubMed ID: 37409509
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia.
Ohta H; Oka H; Usui C; Ohkura M; Suzuki M; Nishioka K
Arthritis Res Ther; 2012 Oct; 14(5):R217. PubMed ID: 23062189
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial.
Arnold LM; Hirsch I; Sanders P; Ellis A; Hughes B
Arthritis Rheum; 2012 Jul; 64(7):2387-97. PubMed ID: 22275142
[TBL] [Abstract][Full Text] [Related]
19. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
[TBL] [Abstract][Full Text] [Related]
20. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study.
Arnold LM; Arsenault P; Huffman C; Patrick JL; Messig M; Chew ML; Sanin L; Scavone JM; Pauer L; Clair AG
Curr Med Res Opin; 2014 Oct; 30(10):2069-83. PubMed ID: 24867298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
